Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5614184

Title:Recombinant human erythropoietin mutants and therapeutic methods employing them
Inventors:Sytkowski, Arthur J.; Arlington, MA, USA
Grodberg, Jennifer; Montreal, Canada
Summary:Disclosed herein are mutant human erythropoietin proteins, methods and uses thereof. The invention relates to DNA encoding modified, secretable erythropoietin proteins with the capacity to regulate the growth and differentiation of red blood cell progenitors. Such proteins are described as differing from wildtype recombinant erythropoietin at the position corresponding to glycine101 of the wildtype erythropoietin, such that the mutant protein has an increased biological activity as determined by an in vitro erythropoietic bioassay. Further disclosed are methods of modifying or altering the regulating activity of a secretable erythropoietin, and applications for the use of such modified secretable erythropoietin proteins. Therapeutic uses are included for both the promotion and the inhibition of red blood cell progenitor growth and differentiation in the treatment of a variety of diseases.
Abstract:
US Patent Website:Click Here for Full Text of Patent
Title Number:US5614184
Application Number:US1995000383743
Date Filed:02/02/1995
Date Published:25/03/1997
Assignee:New England Deaconess Hospital, Boston, MA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/13/2021